Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude observationnelle prospective multicentrique dans le monde réel sur l'HPN en Chine (ReWoPNH)

22 septembre 2026 mis à jour par: AstraZeneca

Une étude observationnelle prospective multicentrique dans le monde réel sur l'hémoglobinurie paroxystique nocturne (HPN) en Chine

As a rare disease listed in the First Catalogue of Rare Diseases in China (National Health Commission of the People's Republic of China, 2019), PNH is poorly studied in China subse-quently leading to the inadequate elucidation of disease characteristics and clinical outcomes. Eculizumab was recently approved by NMPA. The availability of Eculizumab in China pro-vides people living with PNH with a new treatment option that can reduce disease symptoms and prevent the dysregulated complement system from causing further damage. A Phase Ⅳ study is necessary to understand the natural history of disease and the clinical outcomes with different medical interventions.

Aperçu de l'étude

Statut

Complété

Description détaillée

Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare and life-threatening acquired disorder of the pluripotent hematopoietic stem cell and therefore can affect erythrocytes, leukocytes, thrombocytes and probably some endothelial cells. These hematopoietic stem cells have acquired a somatic mutation in the phosphatidylinositol glycan class A (PIG-A) This gene is required for the synthesis of the glycosyl phosphatidyl-inositol (GPI) anchor, which is necessary to attach some proteins to the blood cell membrane. Therefore, a lack of two important complement regulatory proteins is observed on the cell surface: 'decay-accelerating factor' (DAF), also called 'CD55' and 'membrane inhibitor of reactive lysis' (MIRL), also called 'CD59' Thus, red blood cells are more vulnerable to the attack by the complement activation product MAC (complement membrane attack complex). This leads to a complement-mediated intravascular hemolysis. The predisposition of venous thrombosis, hemolytic anemia, complete thrombocytopenia, and thrombosis are the three main characteristics of the disease. Its incidence is not really known but estimated at 0.1~0.6/100 000 per-sons/yr, and prevalence is estimated at 1~4 cases/100,000 persons/yr. PNH was listed in the First Catalogue of Rare Diseases in China, and its incidence was previously reported to be 1/100,000 persons/year, peak onset age 20~40 years.

PNH can be classified into 3 different forms: classical PNH, PNH associated with aplastic anemia (PNH-AA), and subclinical PNH, based on clinical features, bone marrow characteristics, and the size of the mutant clone. The traditional treatment of PNH is still aimed at "protecting" the PNH clone, reducing complement attack and destruction, and alleviating hemolysis with symptomatic supportive therapy. In acute hemolytic episodes, could be administered adrenal glucocorticoids, complemented by cell membrane stabilizers, folic acid, and alkaline drugs. In case of PNH-AA syndrome, treatment with androgens and immunosuppressants may be used; anticoagulation and heparin therapy should be given for the occurrence of thrombosis; other symptomatic supportive treatments include transfusion of red blood cells and platelets if necessary as well as antibacterial drugs in case of infection. Bone marrow transplantation is the only curative therapy for PNH presupposes, but patient need to achieve complete remission with chemotherapy first and a suitable donor is needed.

Besides supportive care, global guidance/consensus also recommend C5 complement inhibitor Eculizumab as a treatment method, and its use could significantly improve 5-year survival rate to 95.5%. Eculizumabis a humanized, first-in-class, anti-C5 antibody that binds with high affinity to C5 and blocks the terminal complement-C5a and C5b-9 formation, reducing the chronic uncontrolled complement activation and its consequences. Eculizumab has been approved for PNH by National Medical Products Administration in August, 2022.

Type d'étude

Observationnel

Inscription (Réel)

724

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Hangzhou, Chine
        • Research Site
    • Anhui
      • Hefei, Anhui, Chine, 230002
        • Research Site
    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine, 100000
        • Research Site
      • Beijing, Beijing Municipality, Chine, 100044
        • Research Site
    • Guangdong
      • Guangzhou, Guangdong, Chine, 510080
        • Research Site
      • Guangzhou, Guangdong, Chine, 510180
        • Research Site
      • Guangzhou, Guangdong, Chine, 510515
        • Research Site
    • Guangxi
      • Nanning, Guangxi, Chine, 530021
        • Research Site
    • Guizhou
      • Guiyang, Guizhou, Chine, 550004
        • Research Site
    • Hebei
      • Shijiazhuang, Hebei, Chine, 050000
        • Research Site
    • Heilongjiang
      • Harbin, Heilongjiang, Chine, 150001
        • Research Site
    • Henan
      • Zhengzhou, Henan, Chine, 450003
        • Research Site
      • Zhengzhou, Henan, Chine, 450052
        • Research Site
      • Zhengzhou, Henan, Chine, 463599
        • Research Site
    • Hubei
      • Wuhan, Hubei, Chine, 430030
        • Research Site
      • Wuhan, Hubei, Chine, 430000
        • Research Site
    • Hunan
      • Changsha, Hunan, Chine, 410008
        • Research Site
      • Changsha, Hunan, Chine, 410005
        • Research Site
    • Jiangsu
      • Nanjing, Jiangsu, Chine, 210029
        • Research Site
      • Nantong, Jiangsu, Chine, 226001
        • Research Site
      • Xuzhou, Jiangsu, Chine, 221002
        • Research Site
    • Jiangxi
      • Nanchang, Jiangxi, Chine, 330006
        • Research Site
      • Nanchang, Jiangxi, Chine, 330008
        • Research Site
    • Jilin
      • Changchun, Jilin, Chine, 130021
        • Research Site
    • Liaoning
      • Shenyang, Liaoning, Chine, 110001
        • Research Site
    • Shandong
      • Jinan, Shandong, Chine, 250000
        • Research Site
      • Qingdao, Shandong, Chine, 266000
        • Research Site
      • Zibo, Shandong, Chine, 255090
        • Research Site
    • Shangdong
      • Linyi, Shangdong, Chine, 276034
        • Research Site
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine, 200040
        • Research Site
      • Shanghai, Shanghai Municipality, Chine, 200336
        • Research Site
    • Shanxi
      • Taiyuan, Shanxi, Chine, 030000
        • Research Site
      • Xi’an, Shanxi, Chine, 710061
        • Research Site
      • Xi’an, Shanxi, Chine, 710068
        • Research Site
    • Sichuan
      • Chengdu, Sichuan, Chine, 610041
        • Research Site
      • Chengdu, Sichuan, Chine, 610072
        • Research Site
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Chine, 300020
        • Research Site
      • Tianjin, Tianjin Municipality, Chine, 300052
        • Research Site
      • Tianjin, Tianjin Municipality, Chine, 300190
        • Research Site
    • Yunnan
      • Kunming, Yunnan, Chine, 650034
        • Research Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Study Population:

Number of patients (estimate): 1000; Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

La description

Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Hemolysis:Concentration of LDH changes at each visit from base-line, of all patients
Délai: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with thrombosis within follow-up
Délai: 12 months

To characterize the progression of PNH

12 months
average number of units of packed RBCs transfused per month, of all patients
Délai: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with renal failure within follow-up
Délai: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with pulmonary hypertension within follow-up
Délai: 12 months

To characterize the progression of PNH

12 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Number and percentage of patients with each symptom of interest within follow-up
Délai: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Demographics at baseline of all patients
Délai: baseline

To describe clinical characteristics of patients with PNH in China

baseline
Number and percentage of patients receiving each type of treatment method at baseline and each visit within follow up, including glucocorticoid, red blood cell transfusion, other supportive treatment, bone marrow transplant, eculizumab, of all patients
Délai: 12 months

To describe the treatment pattern of PNH in China

12 months
All serious adverse events (SAEs)of PNH among eculizumab-treated patients
Délai: 12 months

To describe the safety of Eculizumab treatment via Serious Adverse Events

12 months
Standard descriptive statistics of pregnancy status
Délai: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of lactation status
Délai: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of PNH classification
Délai: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of flow cytometry results
Délai: 12 months

To describe clinical characteristics of patients with PNH in China

12 months

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Concentration of LDH changes at each visit from base-line of PNH among eculizumab-treated patients
Délai: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with thrombosis within follow up among eculizumab-treated patients
Délai: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
average number of units of packed RBCs transfused per month within 12 months v
Délai: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with renal failure within follow up among eculizumab-treated patients
Délai: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with pulmonary hypertension (PH) within follow up among eculizumab-treated patients
Délai: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

10 novembre 2023

Achèvement primaire (Réel)

3 décembre 2025

Achèvement de l'étude (Réel)

3 décembre 2025

Dates d'inscription aux études

Première soumission

30 octobre 2023

Première soumission répondant aux critères de contrôle qualité

23 novembre 2023

Première publication (Réel)

4 décembre 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

24 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

22 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Délai de partage IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Critères d'accès au partage IPD

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner